Jan Keltjens currently serves as Chairman of the Board of Directors of JenaValve Technologies and Vicentra b.v. Both are late-stage startups focused on Structural Hearth respectively Diabetes Management. Besides those, he holds a number of Board roles at high-tech medical device companies. He is also associated with some venture capital funds. This includes a.o. INKEF (Amsterdam), at which he is a member of the Advisory Board, as well as Brightlands Venture Partners, where he chairs the Board of Directors of several funds.

Prior to this, Jan served as Chairman of the Board at NightBalance (acquired by Philips in 2018). Before that, he was the chief executive officer of Sapiens Steering Brain Stimulation (acquired by Medtronic in 2014), chairman and chief executive officer of Endosense SA (acquired by St Jude Medical in 2013), executive chairman of Surpass Medical ltd. (acquired by Stryker Corporation in 2012), as well as president and chief executive officer of AngioDynamics Inc. (NASDAQ; ANGO, 2009 – 2011) and CryoCath Technologies Inc. (TSX; CYT, 2007- until its acquisition by Medtronic in 2009).

From 2000 to 2007, he served as Worldwide General Manager of Cordis Neurovascular, a Johnson & Johnson company. He joined Cordis in 1995 as Vice President and Managing Director responsible for international operations, as well as R&D. Within Cordis, he also served in a number of senior leadership positions in European and Global Marketing. Prior to this, Jan led R&D departments at Unilever and was Managing Director of a group of high-tech service providers.

Mr. Keltjens holds a Master’s degree in Applied Physics from Technical University Eindhoven, the Netherlands.

Mr. Calle Gordo brings 30 years of broad business and management experience in the medical device industry, having served in various executive and managerial roles at Biosensors, Abbott, Guidant, and Eli Lilly.

Up to recently, he was Vice Chairman of the Board of Directors of Biosensors, where he last served as Executive Director and CEO. During his tenure, based in Singapore, he turned around the company’s operating performance, forged strategic alliances, and worked with the largest shareholder to successfully privatize and delist the company in order to create a 1$Bn value global player in interventional cardiology.

He previously led the global team that developed Xience™, a family of drug-eluting stents and market leader for the treatment of coronary artery disease, while serving as Vice President and General Manager of Drug Eluting Stents, Vascular Intervention at Guidant based in California.

As Vice President of Abbott Vascular, based in Brussels, he later managed the international operations of Abbott Vascular outside of the US and led globally the commercial introduction of MitraClip™, a percutaneous treatment for mitral valve repair.

Mr. Calle Gordo also serves as the Chairman of Highlife Medical and serves on the Boards of Lungpacer, FEops, Laminate Medical, and SMT Medical.

Mr. Calle Gordo graduated from Universidad Politecnica de Madrid, Spain, in Biomedical and Electrical Engineering.

Keith Dawkins spent nine years at Boston Scientific Corporation, a $60B medical device company, in a variety of leadership roles, including Global Chief Medical Officer & Executive Vice President; Chief Medical Officer & Senior Vice President, Cardiology, Rhythm & Vascular; Associate Chief Medical Officer & Vice President, Medical Sciences.

As Global Chief Medical Officer & Executive Vice President, he was a member of the Boston Scientific Executive Committee, acting as the Voice of the Patient. He oversaw the clinical function for all six Divisions, as well as leading Medical Affairs in Europe and Latin America, Health Economics in Europe, and Pre-Clinical Sciences for the company. He has worked closely with Regulators, including the FDA, PMDA, and European Agencies. He was Chairman of the Clinical Governance Committee, which provides oversight for all clinical trials undertaken within the company, and he also initiated the Investigator Sponsored Research program which is now in widespread use across all the divisions. He was intimately involved in the Boston Scientific Mergers & Acquisition Strategy, as well as the strategic direction of the clinical trials portfolio. Additionally, he worked closely with the Investor Relations group. During his time at BSC, he transformed the clinical function, improving the strategic and managerial alignment between clinical sciences and the divisions, as well as instigating a robust outsourcing and offshoring process for clinical trial implementation.

Since leaving BSC in early 2017, he remains active in the MedTech sector as a Board Member of Avicena LLC, a Board Member of JenaValve Technology Inc, Chairman of the Board of InnovHeart s.r.l, Senior Advisor to Conformal Medical Inc, and Venture Partner of XGEN Venture SGR S.p.A. He was Chief Medical Officer & Senior Advisor to 4Tech Inc (2017-2020).

Mr. Dearen is President and Chief Financial Officer of Axonics Modulation Technologies, Inc. (Nasdaq: AXNX), a publicly traded medical technology company that manufactures and markets implantable devices to treat overactive bladder (OAB) and stress urinary incontinence (SUI), with sales in 2021 of over $180 million. Mr. Dearen is co-founder of Axonics and has served in his current role for over eight years, during which time the company developed, obtained FDA approval, launched its sacral neuromodulation system to treat OAB, acquired Bulkamid to treat SUI, and completed its IPO in 2018 and four subsequent equity offerings.

Before co-founding Axonics, Mr. Dearen was COO & CFO of Vessix Vascular, a medical device company treating hypertension that was acquired by Boston Scientific in 2012 for $425 million. Previously, he served as Chief Financial Officer of Miraval Holding, Q3DM (acquired by Beckman Coulter), Medication Delivery Devices (acquired by Baxter Healthcare) and was a Principal at Ventana Growth Funds, an international venture capital firm with a portfolio of 53 companies in medical devices, life sciences and healthcare.

Mr. Dearen started his career as a CPA (inactive) in the healthcare group at Ernst & Young in Dallas, Texas. He holds a BBA. in Accounting & Business from Southern Methodist University and an MBA from Boston College and completed the Accredited Public Company Director Certification program at the University of California Los Angeles (UCLA).

Mr. Dearen also serves as an Independent Director and Chair of the Audit Committee on the board of Endotronix, Inc. a privately held digital health and medical technology company dedicated to advancing the treatment of heart failure.

Dr. Andrew Hack has served as Managing Director at Bain Capital Life Sciences since 2019. Andrew currently serves on our Board of Directors and is a member of our Compensation Committee and chairman of our Audit Committee.

Dr. Hack previously served for as Chief Financial Officer of Editas Medicine (Nasdaq: EDIT) and as a healthcare portfolio manager at Millennium Management. Prior to that, he was a securities analyst at a number of healthcare-focused hedge funds and investment banks.

Dr. Hack received an MD and a PhD in molecular genetics and cell biology from the University of Chicago.

John joined JenaValve in 2019 bringing 30 years of experience and is a proven leader in the medical device industry in both start-up organizations and publicly traded companies leading IPO and acquisition strategies.

Throughout his career, John has held several medical device leadership roles. He was the CEO of Endonetics, from 1997 until its acquisition by Medtronic in 2002. From 2002 to 2004, John served as the CEO of Solace Therapeutics. From 2004 until 2010, he was President and CEO at Micrus Endovascular Corporation, leading its IPO efforts in 2005, capturing significant market share and acquisition by Johnson & Johnson in 2010. Before joining JenaValve, John served as the President and CEO of ReVision Optics.

John also serves on the Board of Directors at Cerus Endovascular and CerebroTech Medical Systems, both privately held start-up device medical device companies focused on the treatment of hemorrhagic and diagnosis of ischemic stroke, respectively.

He is a named inventor on more than 20 patents. He has broad and applicable experience leading high-tech medical device emerging growth organizations through market approvals, market access, high growth, and successful strategic transactions, including IPOs and M&A activities.

John received his degree from Cornell University.

Dr. Olivier Litzka has been a partner at Andera Partners, formerly Edmond de Rothschild Investment Partners (EdRIP), since 2006. He has over 15 years’ experience in private equity investments focused on life sciences. Dr. Litzka currently serves on our Board of Directors and is a member of our Compensation Committee.

Dr. Litzka is currently a board member at Allecra Therapeutics GmbH, Autonomic Technologies, Inc., NOXXON Pharma AG, and Supersonic Imagine and was previously a board member at Arvelle Therapeutics, Sapiens Steering Brain Stimulation GmbH, Probiodrug AG, Small Bone Innovations, Inc., and Novexel SA up until their respective acquisition/IPO.

Prior to Andera Partners, Dr. Litzka was a partner at 3i Group PLC where, over his six-year term, he served on the boards of several portfolio companies and made a range of international investments. He started his career as a management consultant with Mercer Management Consulting GmbH.

Dr. Litzka holds a PhD in Molecular Microbiology from the Institut für Mikrobiologie at the University of Munich and completed his scientific research in Munich and Oxford.

Dr. MacLeod has over 35 years of experience in the life sciences and medical devices industries and is currently a partner at Rosetta Capital, a venture capital firm focused on life sciences and medical devices.

Previously, he held senior operating roles in healthcare companies such as Abbott Laboratories and Serono SA. He has held life science fund management roles at SV Health Investors, Paul Capital, and Visium Healthcare Partners. Dr. MacLeod also serves on the board of Oxular Limited and has held previous board roles at Pharming Group N.V. and On-X Life Technologies, Inc., a mechanical heart valve company acquired by Cryogenics Inc.

Dr. MacLeod earned his Bachelor’s Degree in Biological Sciences from the University of Manchester, and his Doctorate of Philosophy from the University of York.

Mr. Nachman has over 25 years of experience in the medical device industry and is currently on the board of several medical device companies, as well as the Arnold and Mable Beckman Foundation, a foundation focused on supporting research in chemistry and life sciences. Previously, he held senior operating roles at Johnson & Johnson, where he was the Company Group Chairman of Cardiovascular and Specialty Solutions and Vision Groups within Johnson & Johnson’s Medical Devices sector. He was a member of the Medical Devices Group Operating Committee and led a diverse portfolio of 6 medical device businesses including Electrophysiology, Neurovascular Intervention, Ear, Nose & Throat, Breast Aesthetics, Optometry and Ophthalmology. Prior to that, Mr. Nachman had various roles with increased scope and responsibilities including Worldwide President of Biosense Webster and Cordis.

Mr. Nachman earned his Bachelor of Science in Management & Economics from the Israel Institute of Technology and a Diploma in Electrical Engineering from the Amal Technical School.